These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 27111731)

  • 21. Novel aminotetrazole derivatives as selective STAT3 non-peptide inhibitors.
    Pallandre JR; Borg C; Rognan D; Boibessot T; Luzet V; Yesylevskyy S; Ramseyer C; Pudlo M
    Eur J Med Chem; 2015 Oct; 103():163-74. PubMed ID: 26352675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lysosome-Targeting Amplifiers of Reactive Oxygen Species as Anticancer Prodrugs.
    Daum S; Reshetnikov MSV; Sisa M; Dumych T; Lootsik MD; Bilyy R; Bila E; Janko C; Alexiou C; Herrmann M; Sellner L; Mokhir A
    Angew Chem Int Ed Engl; 2017 Dec; 56(49):15545-15549. PubMed ID: 28994179
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Novel Tumor-Activated Prodrug Strategy Targeting Ferrous Iron Is Effective in Multiple Preclinical Cancer Models.
    Spangler B; Fontaine SD; Shi Y; Sambucetti L; Mattis AN; Hann B; Wells JA; Renslo AR
    J Med Chem; 2016 Dec; 59(24):11161-11170. PubMed ID: 27936709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel octapeptide-DTX prodrugs targeting MMP-7 as effective agents for the treatment of colorectal cancer with lower systemic toxicity.
    Liu ZY; Tang ML; Ning JF; Hao YP; Zhou L; Sun X
    Eur J Med Chem; 2020 May; 193():112194. PubMed ID: 32203786
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design and synthesis of a pro-drug of vinblastine targeted at treatment of prostate cancer with enhanced efficacy and reduced systemic toxicity.
    Brady SF; Pawluczyk JM; Lumma PK; Feng DM; Wai JM; Jones R; DeFeo-Jones D; Wong BK; Miller-Stein C; Lin JH; Oliff A; Freidinger RM; Garsky VM
    J Med Chem; 2002 Oct; 45(21):4706-15. PubMed ID: 12361397
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and biological evaluations of a monomethylauristatin E glucuronide prodrug for selective cancer chemotherapy.
    Legigan T; Clarhaut J; Renoux B; Tranoy-Opalinski I; Monvoisin A; Jayle C; Alsarraf J; Thomas M; Papot S
    Eur J Med Chem; 2013 Sep; 67():75-80. PubMed ID: 23845743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glutathione-responsive prodrug conjugates for image-guided combination in cancer therapy.
    Ye YX; Wu SY; Chen XY; Yu YW; Zeng SM; Wang ZC; Jiao QC; Zhu HL
    Eur J Med Chem; 2021 Dec; 225():113746. PubMed ID: 34388382
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined treatment targeting HIF-1α and Stat3 is a potent strategy for prostate cancer therapy.
    Reddy KR; Guan Y; Qin G; Zhou Z; Jing N
    Prostate; 2011 Dec; 71(16):1796-809. PubMed ID: 21480310
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Carbonate esters turn camptothecin-unsaturated fatty acid prodrugs into nanomedicines for cancer therapy.
    Li Y; Kang T; Wu Y; Chen Y; Zhu J; Gou M
    Chem Commun (Camb); 2018 Feb; 54(16):1996-1999. PubMed ID: 29411840
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
    Handratta VD; Vasaitis TS; Njar VC; Gediya LK; Kataria R; Chopra P; Newman D; Farquhar R; Guo Z; Qiu Y; Brodie AM
    J Med Chem; 2005 Apr; 48(8):2972-84. PubMed ID: 15828836
    [TBL] [Abstract][Full Text] [Related]  

  • 31. STAT3 inhibition with galiellalactone effectively targets the prostate cancer stem-like cell population.
    Canesin G; Maggio V; Palominos M; Stiehm A; Contreras HR; Castellón EA; Morote J; Paciucci R; Maitland NJ; Bjartell A; Hellsten R
    Sci Rep; 2020 Aug; 10(1):13958. PubMed ID: 32811873
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors: 2. Synthesis and characterization of a novel imide-type prodrug for improving oral absorption.
    Okaniwa M; Imada T; Ohashi T; Miyazaki T; Arita T; Yabuki M; Sumita A; Tsutsumi S; Higashikawa K; Takagi T; Kawamoto T; Inui Y; Yoshida S; Ishikawa T
    Bioorg Med Chem; 2012 Aug; 20(15):4680-92. PubMed ID: 22763369
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and biological studies of the thiols-triggered anticancer prodrug for a more effective cancer therapy.
    Xu Y; Chen J; Li Y; Peng S; Gu X; Sun M; Gao K; Fang J
    Org Biomol Chem; 2015 Mar; 13(9):2634-9. PubMed ID: 25581090
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimization of pyrazole-containing 1,2,4-triazolo-[3,4-b]thiadiazines, a new class of STAT3 pathway inhibitors.
    LaPorte MG; Wang Z; Colombo R; Garzan A; Peshkov VA; Liang M; Johnston PA; Schurdak ME; Sen M; Camarco DP; Hua Y; Pollock NI; Lazo JS; Grandis JR; Wipf P; Huryn DM
    Bioorg Med Chem Lett; 2016 Aug; 26(15):3581-5. PubMed ID: 27381083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prodrug strategy for cancer cell-specific targeting: A recent overview.
    Zhang X; Li X; You Q; Zhang X
    Eur J Med Chem; 2017 Oct; 139():542-563. PubMed ID: 28837920
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and pharmacological screening of a large library of 1,3,4-thiadiazolines as innovative therapeutic tools for the treatment of prostate cancer and melanoma.
    De Monte C; Carradori S; Secci D; D'Ascenzio M; Guglielmi P; Mollica A; Morrone S; Scarpa S; Aglianò AM; Giantulli S; Silvestri I
    Eur J Med Chem; 2015 Nov; 105():245-62. PubMed ID: 26498571
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pro-Nifuroxazide Self-Assembly Leads to Triggerable Nanomedicine for Anti-cancer Therapy.
    Misra SK; Wu Z; Ostadhossein F; Ye M; Boateng K; Schulten K; Tajkhorshid E; Pan D
    ACS Appl Mater Interfaces; 2019 May; 11(20):18074-18089. PubMed ID: 31013055
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sugiol inhibits STAT3 activity via regulation of transketolase and ROS-mediated ERK activation in DU145 prostate carcinoma cells.
    Jung SN; Shin DS; Kim HN; Jeon YJ; Yun J; Lee YJ; Kang JS; Han DC; Kwon BM
    Biochem Pharmacol; 2015 Sep; 97(1):38-50. PubMed ID: 26212545
    [TBL] [Abstract][Full Text] [Related]  

  • 40. "Sweet tooth"-oriented SN38 prodrug delivery nanoplatform for targeted gastric cancer therapy.
    Ding N; Xu S; Zheng S; Ye Q; Xu L; Ling S; Xie S; Chen W; Zhang Z; Xue M; Lin Z; Xu X; Wang L
    J Mater Chem B; 2021 Mar; 9(12):2816-2830. PubMed ID: 33690741
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.